

**Medical University of South Carolina**

**Institutional Biosafety Committee Meeting Minutes**

<b>Meeting Date</b>	Thursday, January 08, 2026
<b>Meeting Time</b>	12:03 PM –1:07 PM
<b>Meeting Type</b>	Teams Meeting
<b>IBC Members Present</b>	1. Caroline Westwater, Ph.D., (IBC Chair) 2. John Woodward, Ph.D. (IBC Vice Chair) 3. Christina Voelkel-Johnson, Ph.D., (BSO) 4. Lisa Steed, Ph.D., (IBC Member) 5. Carlene Brandon, MS. (Local Non-affiliated Member) 6. Natalie Sutkowski, Ph.D. (Member) 7. Aimee McRae-Clar, Pharm.D., BCPP (IBC Alternate Member; Office of Research Integrity Director) 8. Logan Patterson, Ph.D. (IBC Member)
<b>Quorum</b>	Number of Members Present (Voting): 8 Number of Members Not Present: 3 Late Arrival of Voting Members: 0 Early Departure of Voting Members:0
<b>Other Individuals in Attendance</b>	Michael Smith, Ph.D., (IBC Manager) Gloriane Schnabolk Ph.D., (IACUC & IBC Senior Administrator)
<b>Call to Order</b>	The IBC Chair called the meeting to order at 12:04 PM
<b>Conflicts of Interests</b>	The IBC Chair reminded all members present to identify any conflicts of interest before each registration is reviewed.
<b>Review and Approval of Previous Meeting Minutes</b>	December 11, 2025, IBC meeting minutes were tabled to be discussed at the February 12, 2026 IBC meeting.
<b>Review of Prior Business</b>	Discussed IBC Member Training modules in CITI. Discussed training requirements for Co-Investigators and clinical study coordinators.
<b>New IBC Registration and Amendments for Review (repeat for each registration)</b>	

<b>Protocol #</b>	IBC-25-358
<b>PI Name</b>	Strange, Charlie
<b>Study Title</b>	A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of ██████████ in Adults with the PiZZ Genotype Who Have Lung and/or Liver Disease Associated with Severe Alpha-1 Antitrypsin Deficiency (██████████)
<b>Agent</b>	<input checked="" type="checkbox"/> Plasmid DNA/mRNA <input checked="" type="checkbox"/> CRISPR/Cas9 technology <input type="checkbox"/> Molecular grade Escherichia coli <input type="checkbox"/> Laboratory grade strains Saccharomyces cerevisiae <input type="checkbox"/> Replication-deficient viral vectors

	<input type="checkbox"/> RG1 microbes <input type="checkbox"/> RG2 microbes <input type="checkbox"/> Biological toxins <input type="checkbox"/> Gene modified mouse cells <input type="checkbox"/> Gene modified human cells <input type="checkbox"/> Other		
<b>rDNA Category</b>	III-D1a, III-C		
<b>Genetically modified microbes or vectors</b>	N/A		
<b>Transgene expression</b>	tgRNA RNACS24757, mRNA RNAIVT9315, RNACS24757		
<b>Highest BSL</b>	BSL2		
<b>Training</b>	<input checked="" type="checkbox"/> Complete <input type="checkbox"/> Pending		
<b>Risk Assessment of Procedures</b>	PPE is appropriate for <input type="checkbox"/> BSL1 <input checked="" type="checkbox"/> BSL2 <input type="checkbox"/> ABSL1 <input type="checkbox"/> ABSL2 Waste handling: <input checked="" type="checkbox"/> Chemical inactivation <input checked="" type="checkbox"/> Physical inactivation Aerosol handling: N/A <input checked="" type="checkbox"/> Yes <input type="checkbox"/> Centrifugation: N/A <input checked="" type="checkbox"/> Sealed rotors/safety caps <input type="checkbox"/> Sharps handling: N/A <input type="checkbox"/> Standard sharps precautions <input checked="" type="checkbox"/> Transport: N/A <input type="checkbox"/> Double sealed, durable leak-proof container with biohazard label <input checked="" type="checkbox"/> Any special considerations No <input checked="" type="checkbox"/> Yes <input type="checkbox"/>		
<b>Motion</b>	<input type="checkbox"/> Straight approval <input checked="" type="checkbox"/> Conditional approval with administrative post-review <input type="checkbox"/> Conditional approval with subcommittee post-review		
<b>First:</b>	Westwater	<b>Second:</b>	Voelkel-Johnson
<b>Votes</b>			
<b>For:8</b>	Against:0	Abstained:0	Recused:0

<b>Protocol #</b>	IBC-25-348		
<b>PI Name</b>	Rodriguez Blanco, Jezabel		
<b>Study Title</b>	Identifying novel therapeutics for medulloblastoma patients		
<b>Agent</b>	<input checked="" type="checkbox"/> Plasmid DNA/mRNA <input checked="" type="checkbox"/> CRISPR/Cas9 technology <input checked="" type="checkbox"/> Molecular grade Escherichia coli <input type="checkbox"/> Laboratory grade strains Saccharomyces cerevisiae <input checked="" type="checkbox"/> Replication-deficient viral vectors <input type="checkbox"/> RG1 microbes <input type="checkbox"/> RG2 microbes <input type="checkbox"/> Biological toxins <input checked="" type="checkbox"/> Gene modified mouse cells <input checked="" type="checkbox"/> Gene modified human cells <input type="checkbox"/> Other		
<b>rDNA Category</b>	III-D4b, III-D4b		
<b>Genetically modified microbes or vectors</b>	lentivirus		

<b>Transgene expression</b>	p65, IKK2, p65, p53, Stat3, Gli, Smo, NF- $\kappa$ B, Hif1, Hif2, Omomyc, DKK1, B-catenin, Olig2, Myc, EGFP, GFP, RFP, YFP, luciferase		
<b>Highest BSL</b>	BSL1, ABSL1		
<b>Training</b>	<input checked="" type="checkbox"/> Complete <input type="checkbox"/> Pending		
<b>Risk Assessment of Procedures</b>	PPE is appropriate for <input checked="" type="checkbox"/> BSL1 <input type="checkbox"/> BSL2 <input checked="" type="checkbox"/> ABSL1 <input type="checkbox"/> ABSL2 Waste handling: <input checked="" type="checkbox"/> Chemical inactivation <input checked="" type="checkbox"/> Physical inactivation Aerosol handling: N/A <input type="checkbox"/> Yes <input checked="" type="checkbox"/> Centrifugation: N/A <input type="checkbox"/> Sealed rotors/safety caps <input checked="" type="checkbox"/> Sharps handling: N/A <input type="checkbox"/> Standard sharps precautions <input checked="" type="checkbox"/> Transport: N/A <input type="checkbox"/> Double sealed, durable leak-proof container with biohazard label <input checked="" type="checkbox"/> Any special considerations No <input checked="" type="checkbox"/> Yes <input type="checkbox"/>		
<b>Motion</b>	<input type="checkbox"/> Straight approval <input checked="" type="checkbox"/> Conditional approval with administrative post-review <input type="checkbox"/> Conditional approval with subcommittee post-review		
<b>First:</b>	Voelkel-Johnson	<b>Second:</b>	Westwater
<b>Votes</b>			
<b>For:8</b>	<b>Against:0</b>	<b>Abstained:0</b>	<b>Recused:0</b>

<b>Protocol #</b>	IBC-25-356		
<b>PI Name</b>	Penrod-Martin, Rachel		
<b>Study Title</b>	Mouse Behavior Phenotyping Core IBC		
<b>Agent</b>	<input type="checkbox"/> Plasmid DNA/mRNA <input type="checkbox"/> CRISPR/Cas9 technology <input type="checkbox"/> Molecular grade Escherichia coli <input type="checkbox"/> Laboratory grade strains Saccharomyces cerevisiae <input type="checkbox"/> Replication-deficient viral vectors <input type="checkbox"/> RG1 microbes <input type="checkbox"/> RG2 microbes <input type="checkbox"/> Biological toxins <input type="checkbox"/> Gene modified mouse cells <input type="checkbox"/> Gene modified human cells <input type="checkbox"/> Other:		
<b>rDNA Category</b>	III-D4b		
<b>Genetically modified microbes or vectors</b>	Core user defined		
<b>Transgene expression</b>	Core user define		
<b>Highest BSL</b>	BSL2, ABSL2		
<b>Training</b>	<input checked="" type="checkbox"/> Complete <input type="checkbox"/> Pending		
<b>Risk Assessment of Procedures</b>	PPE is appropriate for <input type="checkbox"/> BSL1 <input checked="" type="checkbox"/> BSL2 <input type="checkbox"/> ABSL1 <input checked="" type="checkbox"/> ABSL2 Waste handling: <input checked="" type="checkbox"/> Chemical inactivation <input checked="" type="checkbox"/> Physical inactivation		

	Aerosol handling: N/A <input checked="" type="checkbox"/> Yes <input type="checkbox"/> Centrifugation: N/A <input checked="" type="checkbox"/> Sealed rotors/safety caps <input type="checkbox"/> Sharps handling: N/A <input type="checkbox"/> Standard sharps precautions <input checked="" type="checkbox"/> Transport: N/A <input type="checkbox"/> Double sealed, durable leak-proof container with biohazard label <input checked="" type="checkbox"/> Any special considerations No <input checked="" type="checkbox"/> Yes <input type="checkbox"/>		
<b>Motion</b>	<input type="checkbox"/> Straight approval <input checked="" type="checkbox"/> Conditional approval with administrative post-review <input type="checkbox"/> Conditional approval with subcommittee post-review		
First:	Voelkel-Johnson	Second:	Westwater
<b>Votes</b>			
For:8	Against:0	Abstained:0	Recused:0

<b>Meeting Adjournment</b>	The IBC Chair called for the meeting to be adjourned at 1:07 PM
----------------------------	---